Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: Results of a randomized trial

Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo, Carlo Bodenizza, Nicola Cascavilla, Lorella Melillo, Potito Rosario Scalzulli, Matteo Dell'Olio, Antonio La Sala, Saverio Mantuano, Michele Nobile, Angelo Michele Carella

Research output: Contribution to journalArticle

Abstract

Ninety patients with untreated, stage I-II A myeloma, were randomised to receive or not monthly infusions of pamidronate (PMD) for 1 year, without additional therapies. Follow-up ranged from 36 to 72 months (median 51 months). Three years after the start of the treatment, the disease had progressed in 25% of PMD treated patients and in 26.8% of controls (p n.s). Median time-to-progression was 16 and 17.4 months, respectively (p n.s). Among the 21 patients who required chemo-radiotherapy, skeletal events (osteolytic lesions, pathological fractures and/or hypercalcemia) developed in 9/11 (81.8%) controls and in 4/10 (40%) of treated patients (p <0.01). "Prophylactic" administration of PMD may decrease the development of skeletal events, but does not reduce the rate and the time of disease progression in early-stage myeloma.

Original languageEnglish
Pages (from-to)1545-1548
Number of pages4
JournalLeukemia and Lymphoma
Volume44
Issue number9
DOIs
Publication statusPublished - Sep 1 2003

Keywords

  • Bisphosphonates
  • Monoclonal gammopathies
  • Myeloma
  • Pamidronate
  • Zoledronate

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: Results of a randomized trial'. Together they form a unique fingerprint.

  • Cite this